2005
Cardiac tumors, cardiac manifestations of systemic diseases, and traumatic cardiac injury.
Colucci WS, Price DT. Cardiac tumors, cardiac manifestations of systemic diseases, and traumatic cardiac injury. Harrison’s Principles of Internal Medicine, 16th editionBooks
2003
Short- and Long-Term COX-2 Inhibition Reverses Endothelial Dysfunction in Patients With Hypertension
Widlansky ME, Price DT, Gokce N, Eberhardt RT, Duffy SJ, Holbrook M, Maxwell C, Palmisano J, Keaney JF, Morrow JD, Vita JA. Short- and Long-Term COX-2 Inhibition Reverses Endothelial Dysfunction in Patients With Hypertension. Hypertension 2003, 42: 310-315. PMID: 12874094, DOI: 10.1161/01.hyp.0000084603.93510.28.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnalysis of VarianceBlood PressureBrachial ArteryCelecoxibCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDouble-Blind MethodEndothelium, VascularFemaleHumansHypertensionIsoenzymesMaleMembrane ProteinsMiddle AgedNitroglycerinProstaglandin-Endoperoxide SynthasesProstaglandinsPyrazolesSulfonamidesTime FactorsVasodilationConceptsFlow-mediated dilationEndothelial dysfunctionUrinary concentrationsCelecoxib treatmentBrachial artery flow-mediated dilationArtery flow-mediated dilationEndothelium-derived nitric oxideSelective cyclooxygenase-2 inhibitor celecoxibBrachial artery vasodilator functionBaseline arterial diameterCyclooxygenase-2 productsCyclooxygenase-2 inhibitor celecoxibDouble-blind studyNitroglycerin-mediated dilationWeeks of treatmentCyclooxygenase-2 activityCyclooxygenase-2 inhibitionCyclooxygenase-2 inhibitorProstacyclin metaboliteVasoconstrictor prostanoidsVasodilator functionHypertensive patientsFirst doseEndothelial functionPlacebo treatment
2000
Redox Control of Vascular Nitric Oxide Bioavailability
Price D, Vita J, Keaney J. Redox Control of Vascular Nitric Oxide Bioavailability. Antioxidants & Redox Signaling 2000, 2: 919-935. PMID: 11213492, DOI: 10.1089/ars.2000.2.4-919.BooksConceptsVascular nitric oxide bioavailabilityImportant public health implicationsNitric oxide bioavailabilityVascular oxidative stressPublic health implicationsVascular diseaseVascular homeostasisAntioxidant stressOxidative stressBiologic activityDisease statesHealth implicationsDiseaseHuman diseasesClear mechanismComparison of cardiovascular adaptations to long-term arm and leg exercise in wheelchair athletes versus long-distance runners.
Price DT, Davidoff R, Balady GJ. Comparison of cardiovascular adaptations to long-term arm and leg exercise in wheelchair athletes versus long-distance runners. The American Journal Of Cardiology 2000, 85: 996-1001. PMID: 10760342, DOI: 10.1016/s0002-9149(99)00917-0.Peer-Reviewed Original Research
1999
Cellular adhesion molecules and atherogenesis.
Price DT, Loscalzo J. Cellular adhesion molecules and atherogenesis. The American Journal Of Medicine 1999, 107: 85-97. PMID: 10403357, DOI: 10.1016/s0002-9343(99)00153-9.Books
1998
Factor V Leiden mutation as a risk factor for recurrent pregnancy loss.
Ridker PM, Miletich JP, Buring JE, Ariyo AA, Price DT, Manson JE, Hill JA. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Annals Of Internal Medicine 1998, 128: 1000-3. PMID: 9625662, DOI: 10.7326/0003-4819-128-12_part_1-199806150-00007.Peer-Reviewed Original Research
1997
Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.
Price DT, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Annals Of Internal Medicine 1997, 127: 895-903. PMID: 9382368, DOI: 10.7326/0003-4819-127-10-199711150-00007.Books